304 related articles for article (PubMed ID: 37004045)
21. Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM.
Rong D; Su Y; Jia D; Zeng Z; Yang Y; Wei D; Lu H; Cao Y
Front Immunol; 2024; 15():1387316. PubMed ID: 38660305
[TBL] [Abstract][Full Text] [Related]
22. The role of NLRP3 in the prognosis and immune infiltrates of skin cutaneous melanoma (SKCM).
Wu S; Zang Q; Dai B
Transl Cancer Res; 2021 Apr; 10(4):1692-1702. PubMed ID: 35116494
[TBL] [Abstract][Full Text] [Related]
23. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
[TBL] [Abstract][Full Text] [Related]
24. FANCI serve as a prognostic biomarker correlated with immune infiltrates in skin cutaneous melanoma.
Cai Z; Duan Y; Li W; Liu Z; Gong Z; Hong S; He X; Xuanyuan X; Chen Y; Bi X; Wang W
Front Immunol; 2023; 14():1295831. PubMed ID: 38077326
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of SNHG16(lncRNA)-Hsa-Let-7b-5p(miRNA)-TUBB4A (mRNA) Pathway Fuels Progression of Skin Cutaneous Melanoma.
Chen G; Yan J
Curr Protein Pept Sci; 2022; 23(11):791-809. PubMed ID: 36173063
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
[TBL] [Abstract][Full Text] [Related]
27. Identification of CXCL13 as an Immune-Related Biomarker Associated with Tumorigenesis and Prognosis in Cutaneous Melanoma Patients.
Si Z; Hu H
Med Sci Monit; 2021 Jul; 27():e932052. PubMed ID: 34247183
[TBL] [Abstract][Full Text] [Related]
28. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
[TBL] [Abstract][Full Text] [Related]
29. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Liu X; Wang J
Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
[TBL] [Abstract][Full Text] [Related]
30. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W
Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma.
Jiang Y; Zhang C; Zhang J; Han D; Shi X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108344. PubMed ID: 34763233
[TBL] [Abstract][Full Text] [Related]
32. Identification of aberrantly methylated differentially expressed genes and pro-tumorigenic role of KIF2C in melanoma.
Huang CH; Han W; Wu YZ; Shen GL
Front Genet; 2022; 13():817656. PubMed ID: 35991567
[No Abstract] [Full Text] [Related]
33. Establishment of skin cutaneous melanoma prognosis model based on vascular mimicry risk score.
Wang Y; Zou L; Song M; Zong J; Wang S; Meng L; Jia Z; Zhao L; Han X; Lu M
Medicine (Baltimore); 2024 Feb; 103(7):e36679. PubMed ID: 38363903
[TBL] [Abstract][Full Text] [Related]
34. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
35. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract][Full Text] [Related]
36. HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.
He S; Ding Y; Ji Z; Yuan B; Chen J; Ren W
Cancer Cell Int; 2023 Jun; 23(1):122. PubMed ID: 37344870
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma.
Yang H; Che D; Gu Y; Cao D
Front Genet; 2022; 13():940306. PubMed ID: 36110204
[No Abstract] [Full Text] [Related]
38. Combined signature of G protein-coupled receptors and tumor microenvironment provides a prognostic and therapeutic biomarker for skin cutaneous melanoma.
Song B; Wang K; Peng Y; Zhu Y; Cui Z; Chen L; Yu Z; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18135-18160. PubMed ID: 38006451
[TBL] [Abstract][Full Text] [Related]
39. Development of a biomarker signature associated with anoikis to predict prognosis and immunotherapy response in melanoma.
Wu Z; Zhang R; Bao J; Yin M; Wang X
Arch Dermatol Res; 2024 May; 316(6):219. PubMed ID: 38787413
[TBL] [Abstract][Full Text] [Related]
40. KIF4A functions as a diagnostic and prognostic biomarker and regulates tumor immune microenvironment in skin cutaneous melanoma.
Zeng S; Wang Q; Zhou R; Wang D
Pathol Res Pract; 2024 Feb; 254():155166. PubMed ID: 38286055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
